• Dev R Puri, Leonard H Wexler, Paul A Meyers, Michael P La Quaglia, John H Healey, and Suzanne L Wolden.
• Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
• Int. J. Radiat. Oncol. Biol. Phys. 2006 Jul 15; 65 (4): 1177-84.

PurposeTo evaluate local control and toxicity for very young children treated with multimodality therapy for rhabdomyosarcoma (RMS).Methods And MaterialsFrom 1990 to 2004, 20 patientsor=1 year after diagnosis (15) in terms of mild, moderate, or severe deficits.ResultsMedian follow-up was 33 months for survivors and 23 months for all patients. Two-year actuarial local control, event-free survival, disease-specific survival, and overall survival were 84%, 52%, 74%, and 62%, respectively. All patients who began EBRTConclusionsA reduced dose of 36-Gy EBRT after delayed GTR may maximize local control while minimizing long-term sequelae for very young children with RMS, but unresectable tumors (e.g., parameningeal) require higher doses. Normal-tissue-sparing techniques such as intensity-modulated radiation therapy and IOHDR are encouraged. Local control may be maximized when EBRT begins

21 keywords...

hide…